Research map: MYC in Oncogenesis and Therapeutic Implications

Back to the article

Papers in this map

  1. Cell cycle regulation: p53-p21-RB signaling · Kurt Engeland · 2022 · 1340 citations · Cited by this paper
  2. Epilepsy: Epidemiology, Molecular Pathogenesis, and Clinical Management · 2026 · Related
  3. Therapeutic targeting of “undruggable” MYC · Víctor Llombart · 2021 · 504 citations · Cited by this paper
  4. Preoperative Albumin Infusion Reduced Pulmonary Complications in Elderly Patients With Hypoalbuminemia Undergoing Cardiac Surgery: A Single‐Center, Randomized, Double‐Blind, Controlled Pilot Trial · 2026 · Related
  5. Diverse alterations associated with resistance to KRAS(G12C) inhibition · Yulei Zhao · 2021 · 474 citations · Cited by this paper
  6. CD8 + Tissue‐Resident Memory T Cells in Health and Disease · 2026 · Related
  7. A proteogenomic portrait of lung squamous cell carcinoma · Shankha Satpathy · 2021 · 404 citations · Cited by this paper
  8. Lymphatic Endothelial Cells in Health and Disease · 2026 · Related
  9. ecDNA hubs drive cooperative intermolecular oncogene expression · King L. Hung · 2021 · 366 citations · Cited by this paper
  10. Nicotinamide N‐Methyltransferase Epigenetically Activates Fibronectin 1 Through H3K9me3 Remodeling in Clear Cell Renal Cell Carcinoma · 2026 · Related
  11. Ribosome biogenesis in disease: new players and therapeutic targets · Lijuan Jiao · 2023 · 339 citations · Cited by this paper
  12. Markers Predicting Cure With Combinatorial Treatment in a Mouse Model of Latent Autoimmune Diabetes in Adults · 2026 · Related
  13. Cancer‐associated fibroblasts in breast cancer: Challenges and opportunities · Dengdi Hu · 2022 · 291 citations · Cited by this paper
  14. Metabolic Regulation of Macrophages in Health and Disease · 2026 · Related
  15. p21 produces a bioactive secretome that places stressed cells under immunosurveillance · Ines Sturmlechner · 2021 · 288 citations · Cited by this paper
  16. MAX in cancer: dynamic role of MYC’s partner-in-crime · 2026 · Related
  17. Signaling pathways in cancer‐associated fibroblasts: recent advances and future perspectives · Zengli Fang · 2022 · 288 citations · Cited by this paper
  18. Targeting Myc through BET-PROTAC elicits potent anti-lymphoma activity in diffuse large B cell lymphoma · 2025 · Related
  19. Cancer cell plasticity: from cellular, molecular, and genetic mechanisms to tumor heterogeneity and drug resistance · Gh. Rasool Bhat · 2024 · 281 citations · Cited by this paper
  20. MYC as a Target for Cancer Treatment: from Undruggable to Druggable? · 2025 · Related
  21. Mechanisms of Resistance to Oncogenic KRAS Inhibition in Pancreatic Cancer · Julien Dilly · 2024 · 274 citations · Cited by this paper
  22. H3K18 Lactylation Potentiates Immune Escape of Non–Small Cell Lung Cancer · Cai Zhang · 2024 · 260 citations · Cited by this paper
  23. Tumor cell plasticity in targeted therapy-induced resistance: mechanisms and new strategies · Zhenduo Shi · 2023 · 255 citations · Cited by this paper
  24. Cancer associated fibroblasts in cancer development and therapy · Hongyuan Jia · 2025 · 217 citations · Cited by this paper
  25. An allosteric pan-TEAD inhibitor blocks oncogenic YAP/TAZ signaling and overcomes KRAS G12C inhibitor resistance · Thijs J. Hagenbeek · 2023 · 212 citations · Cited by this paper
  26. Tumour-selective activity of RAS-GTP inhibition in pancreatic cancer · Urszula N. Wasko · 2024 · 202 citations · Cited by this paper
  27. MYC targeting by OMO-103 in solid tumors: a phase 1 trial · Elena Garralda · 2024 · 196 citations · Cited by this paper
  28. NCAPD3 enhances Warburg effect through c-myc and E2F1 and promotes the occurrence and progression of colorectal cancer · Zuolei Jing · 2022 · 184 citations · Cited by this paper
  29. Hypoxia-induced exosomal circPDK1 promotes pancreatic cancer glycolysis via c-myc activation by modulating miR-628-3p/BPTF axis and degrading BIN1 · Jiewei Lin · 2022 · 180 citations · Cited by this paper
  30. c-MYC mediates the crosstalk between breast cancer cells and tumor microenvironment · Fangyan Gao · 2023 · 180 citations · Cited by this paper
  31. Targeting Aurora B kinase prevents and overcomes resistance to EGFR inhibitors in lung cancer by enhancing BIM- and PUMA-mediated apoptosis · Kosuke Tanaka · 2021 · 176 citations · Cited by this paper
  32. Epithelial–mesenchymal transition: The history, regulatory mechanism, and cancer therapeutic opportunities · Zhao Jie Huang · 2022 · 173 citations · Cited by this paper
  33. Nano drug delivery systems for antisense oligonucleotides (ASO) therapeutics · Thiruganesh Ramasamy · 2022 · 173 citations · Cited by this paper
  34. MYC: a complex problem · Subhendu Das · 2022 · 165 citations · Cited by this paper
  35. P-TEFb: The master regulator of transcription elongation · Koh Fujinaga · 2023 · 164 citations · Cited by this paper
  36. Molecular Subtypes of Primary SCLC Tumors and Their Associations With Neuroendocrine and Therapeutic Markers · Song Qu · 2021 · 161 citations · Cited by this paper
  37. Cancer associated fibroblasts and metabolic reprogramming: unraveling the intricate crosstalk in tumor evolution · Fusheng Zhang · 2024 · 145 citations · Cited by this paper
  38. The STAT3-MYC axis promotes survival of leukemia stem cells by regulating SLC1A5 and oxidative phosphorylation · Maria L. Amaya · 2021 · 144 citations · Cited by this paper
  39. Single‐Cell Transcriptome Analysis Uncovers Intratumoral Heterogeneity and Underlying Mechanisms for Drug Resistance in Hepatobiliary Tumor Organoids · Yan Zhao · 2021 · 137 citations · Cited by this paper

Source: OpenAlex (CC0)